pharmaphorum

JANUARY 6, 2021

The regulator said it wanted more long-term safety and efficacy data from the REGENERATE study before making a final decision on the drug, which had been expected to be the first entrant into a likely multi-billion dollar market niche. The post High hopes as Inventiva takes NASH contender into phase 3 appeared first on.

Gene Silencing 52

Gene Silencing Regulation Pharma Companies Trials 52

pharmaphorum

DECEMBER 23, 2020

The results also suggest further uses for the drug in early disease and more revenues to come from one of the company’s biggest success stories from the last decade. Biogen and Denali will co-market the lead LRRK2 product in the US and China, and Biogen will commercialise in all other markets.

Marketing 96

Marketing Gene Gene Silencing Drugs 96

Delveinsight

AUGUST 6, 2020

The Hereditary Transthyretin Amyloidosis (hATTR) Market size in the 7MM was estimated to be USD 306.9 Among the 7MM geographies, the US accounted for the 54% share of the total hATTR market size. hATTR Market: Present Treatment Options. Gene-silencing Therapies. hATTR market : In The Pipeline.

Protein 52

Protein Gene Silencing Marketing Gene 52